The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

StocksUpdated•Originally published 28 April 2026•Updated 28 April 2026•

1 min read

Novartis CEO Warns of Challenges Under Trump’s Drug Pricing Policies

Key Facts

1Novartis' CEO warned that U.S. drug pricing policy under President Donald Trump poses a very difficult situation.

2The CEO expects the reality of the drug pricing policy to set in over the next 18 months.

The CEO of Novartis has issued a warning regarding U.S. drug pricing policies under President Donald Trump, describing the current environment as a very difficult situation. The company reported first-quarter earnings that missed analyst expectations, primarily due to intensifying generic competition within the key U.S. market. CEO Vas Narasimhan characterized the first two quarters of the year as being 'bumpy' as the firm navigates these headwinds. According to the CEO, the full impact of regulatory shifts and pricing pressures is expected to manifest over the next 18 months. This financial underperformance underscores industry concerns regarding revenue sustainability under increased political scrutiny. Major drugmakers continue to face uncertainty as they adapt to the evolving healthcare agenda in their largest global market.

about 1 month ago

Version History

Version 1about 1 month ago

What changed: The story was updated to include the Q1 earnings miss and the CEO's comments regarding a 'bumpy' outlook for the first half of the year due to generic competition.